Gaebler’s work—a longitudinal analysis of SARS-CoV-2-specific humoral responses in 87 patients—showed that anti-SARS-CoV-2 RBD IgM and IgG antibody titers decrease significantly with IgA being less affected, and that memory B cells with anti-SARS-CoV-2 RBD IgA generating potency persisted for up to six months after infection and exhibited increased neutralization potency [26]. The gene discussed is CD79A; the disease is infection.